Chargement en cours…
A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
BACKGROUND: There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD). METHODS: A Value-Based Medicine, 12-year, combined-eye model, cost-utility analysis evaluated genetic testing of Category 3 AMD...
Auteurs principaux: | , , , , |
---|---|
Format: | Online Article Texte |
Langue: | English |
Publié: |
BioMed Central
2015
|
Sujets: | |
Accès en ligne: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088478/ https://www.ncbi.nlm.nih.gov/pubmed/27847612 http://dx.doi.org/10.1186/s40942-015-0016-5 |